JGC
ABEO icon

J. Goldman & Co’s Abeona Therapeutics ABEO Stock Holding History

J. Goldman & Co’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.19M Buy
678,173
+37,643
+6% +$207K 0.11% 230
2026
Q1 		$2.87M Buy
640,530
+241,614
+61% +$1.21M 0.08% 263
2025
Q4 		$2.1M Buy
+398,916
New +$2.01M 0.06% 308
2024
Q2 		– Sell
-22,750
Closed -$165K – 427
2024
Q1 		$165K Sell
22,750
-407,066
-95% -$2.58M 0.01% 370
2023
Q4 		$2.15M Sell
429,816
-65,519
-13% -$288K 0.09% 181
2023
Q3 		$2.09M Sell
495,335
-2,709
-0.5% -$10.3K 0.07% 200
2023
Q2 		$2.01M Buy
+498,044
New +$1.74M 0.07% 209
2018
Q2 		– Sell
-5,907
Closed -$2.12M – 347
2018
Q1 		$2.12M Sell
5,907
-364
-6% -$135K 0.09% 207
2017
Q4 		$2.48M Buy
6,271
+5,343
+576% +$2.21M 0.13% 178
2017
Q3 		$396K Sell
928
-11,272
-92% -$3.03M 0.02% 279
2017
Q2 		$1.95M Buy
12,200
+824
+7% +$112K 0.11% 181
2017
Q1 		$1.42M Buy
+11,376
New +$1.47M 0.07% 232

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

J. Goldman & Co's ABEO Position: Q2 2026 in Review

J. Goldman & Co increased its Abeona Therapeutics (ABEO) stake by 5.9% in Q2 2026, buying an estimated $207K and bringing the position to 678,173 shares worth $4.19M. The position accounts for 0.11% of the portfolio, ranked #230.

J. Goldman & Co first reported a position in ABEO in Q1 2017 and has held it in 12 quarters since. 127 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • J. Goldman & Co held 678,173 shares of Abeona Therapeutics worth $4.19M as of Q2 2026.
  • J. Goldman & Co bought 37,643 Abeona Therapeutics shares in Q2 2026, an estimated $207K.
  • Abeona Therapeutics made up 0.11% of J. Goldman & Co's portfolio in Q2 2026, its #230 holding.
  • J. Goldman & Co first reported a position in Abeona Therapeutics in Q1 2017 and has held it in 12 quarters since.
  • 127 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.